Arcutis Biotherapeutics Inc

Research Arcutis Biotherapeutics Inc (ARQT) on Bullrun: market cap USD 3.35B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerARQT
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 3.35B
• Financial periodFY2025
• RevenueUSD 376.07M
• Revenue growth91.3%
• Net income-USD 16.14M
• Free cash flow-USD 6.31M
• Gross margin90.2%

Valuation Snapshot

latest market cap is USD 3.35B.

About Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc.

Frequently asked questions

What is Arcutis Biotherapeutics Inc's market cap?

Arcutis Biotherapeutics Inc's market capitalization is USD 3.35B.

What does Arcutis Biotherapeutics Inc do?

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.